Cytokine responses to EHV-1 infection in immune and non-immune ponies
- PMID: 16473413
- DOI: 10.1016/j.vetimm.2006.01.013
Cytokine responses to EHV-1 infection in immune and non-immune ponies
Abstract
Protecting equids against equine herpesvirus-1 (EHV-1) infection remains an elusive goal. Repeated infection with EHV-1 leads to protective immunity against clinical respiratory disease, and a study was conducted to measure the regulatory cytokine response (IFN-gamma and IL-4) in repeatedly infected immune ponies compared to non-immune ponies. Two groups of four ponies were established. Group 1 ponies had previously been infected on two occasions, and most recently 7 months before this study. Group 2 ponies had no history no vaccination or challenge infection prior to this study. Both groups were subjected to an intranasal challenge infection with EHV-1, and blood samples were collected pre-infection, and at 7 and 21 days post-infection for preparation of PBMCs. At each time point, the in vitro responses of PBMCs to stimulation with EHV-1 were measured, including IFN-gamma and IL-4 mRNA production, and lymphoproliferation. Group 1 ponies showed no signs of clinical disease or viral shedding after challenge infection. Group 2 ponies experienced a biphasic pyrexia, mucopurulent nasal discharge, and nasal shedding of virus after infection. Group 1 ponies had an immune response characterized both before and subsequent to challenge infection by an IFN-gamma response to EHV-1 in the absence of an IL-4 response, and demonstrated increased EHV-1-specific lymphoproliferation post-infection. Group 2 ponies had limited cytokine or lymphoproliferative responses to EHV-1 pre-challenge, and demonstrated increases in both IFN-gamma and IL-4 responses post-challenge, but without any lymphoproliferative response. Protective immunity to EHV-1 infection was therefore characterized by a polarized IFN-gamma dependent immunoregulatory cytokine response.
Similar articles
-
Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies.Vet Immunol Immunopathol. 2006 May 15;111(1-2):81-95. doi: 10.1016/j.vetimm.2006.01.011. Epub 2006 Mar 23. Vet Immunol Immunopathol. 2006. PMID: 16549215
-
Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.Vet Immunol Immunopathol. 2006 May 15;111(1-2):47-57. doi: 10.1016/j.vetimm.2006.01.008. Epub 2006 Mar 31. Vet Immunol Immunopathol. 2006. PMID: 16580075 Clinical Trial.
-
Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection.Vaccine. 2006 Mar 6;24(10):1490-500. doi: 10.1016/j.vaccine.2005.10.019. Epub 2005 Oct 21. Vaccine. 2006. PMID: 16269205
-
The equine immune response to equine herpesvirus-1: the virus and its vaccines.Vet Immunol Immunopathol. 2006 May 15;111(1-2):15-30. doi: 10.1016/j.vetimm.2006.01.005. Epub 2006 Feb 14. Vet Immunol Immunopathol. 2006. PMID: 16476492 Review.
-
Immune escape of equine herpesvirus 1 and other herpesviruses of veterinary importance.Vet Immunol Immunopathol. 2006 May 15;111(1-2):31-40. doi: 10.1016/j.vetimm.2006.01.006. Epub 2006 Feb 10. Vet Immunol Immunopathol. 2006. PMID: 16472872 Review.
Cited by
-
Characterizing the Pathogenesis and Immune Response of Equine Herpesvirus 8 Infection in Lung of Mice.Animals (Basel). 2022 Sep 20;12(19):2495. doi: 10.3390/ani12192495. Animals (Basel). 2022. PMID: 36230234 Free PMC article.
-
Impact of the host immune response on the development of equine herpesvirus myeloencephalopathy in horses.J Gen Virol. 2024 May;105(5):001987. doi: 10.1099/jgv.0.001987. J Gen Virol. 2024. PMID: 38767608 Free PMC article.
-
Equine PBMC Cytokines Profile after In Vitro α- and γ-EHV Infection: Efficacy of a Parapoxvirus Ovis Based-Immunomodulator Treatment.Vaccines (Basel). 2017 Sep 19;5(3):28. doi: 10.3390/vaccines5030028. Vaccines (Basel). 2017. PMID: 28925977 Free PMC article.
-
Effect of a single point mutation on equine herpes virus 9 (EHV-9) neuropathogenicity after intranasal inoculation in a hamster model.J Vet Med Sci. 2017 Aug 18;79(8):1426-1436. doi: 10.1292/jvms.17-0076. Epub 2017 Jul 15. J Vet Med Sci. 2017. PMID: 28717112 Free PMC article.
-
Deletion of the ORF2 gene of the neuropathogenic equine herpesvirus type 1 strain Ab4 reduces virulence while maintaining strong immunogenicity.BMC Vet Res. 2018 Aug 22;14(1):245. doi: 10.1186/s12917-018-1563-4. BMC Vet Res. 2018. PMID: 30134896 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources